Money in hand, Alcobra focuses ‘attention’ on ADHD
By Marie Powers
Thursday, February 6, 2014
Alcobra Ltd. didn’t set out to address attention deficit hyperactivity disorder (ADHD), an indication with a number of approved drugs – including Ritalin (methylphenidate, Novartis AG), Concerta (a different formulation of methylphenidate, Johnson & Johnson) and Adderall XR (d-amphetamine, Shire plc) – as well as spectacular failures.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.